QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 dario-expands-glp-1-solution-client-base-with-new-employer-contract-financial-terms-not-disclosed

Dario's leading behavior change solutions continue to win interest in the employer, payer and pharmaceutical markets

 dariohealth-q1-sales-5758m-miss-6758m-estimate

DarioHealth (NASDAQ:DRIO) reported quarterly sales of $5.758 million which missed the analyst consensus estimate of $6.758 mill...

 dario-publishes-new-peer-reviewed-study-that-deepens-the-body-of-evidence-that-managing-cardiometabolic-conditions-in-one-integrated-platform-improves-clinical-outcomes

Quasi-randomized study demonstrates the value of Dario's integrated approach to provide one solution for members to manage ...

 dario-signs-two-employers-for-cardiometabolic-suite-with-integrated-glp-1-solution-beginning-in-q2-of-2024

Dario selected to provide integrated and proven solutions to improve employee cardiometabolic healthNEW YORK, April 18, 2024 /P...

 dario-publishes-two-peer-reviewed-studies-demonstrating-impact-of-digital-behavioral-health

Studies include a Randomized Controlled Trial demonstrating significant reduction in perceived stress for teens

 two-national-employers-select-darios-integrated-chronic-condition-solution-to-improve-employee-health

DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, annou...

 stifel-maintains-buy-on-dariohealth-maintains-4-price-target

Stifel analyst David Grossman maintains DarioHealth (NASDAQ:DRIO) with a Buy and maintains $4 price target.

 dariohealth-q4-eps-041-beats-054-estimate

DarioHealth (NASDAQ:DRIO) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.54) b...

 dariohealth-q4-sales-362m-beat-357m-estimate

DarioHealth (NASDAQ:DRIO) reported quarterly sales of $3.62 million which beat the analyst consensus estimate of $3.57 million ...

 earnings-scheduled-for-march-28-2024

Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per ...

 earnings-outlook-for-dariohealth
Earnings Outlook For DarioHealth
03/27/2024 17:00:55

 new-research-from-dario-demonstrates-ability-to-deliver-improved-health-outcomes-with-integrated-solution-for-members-managing-weight-and-blood-glucose-with-or-without-glp-1-medications

Study presented at ATTD 2024 is the first of a planned series examining the impact of Dario's integrated cardiometabolic so...

 concurrent-to-twill-acquisition-deal-dariohealth-priced-224m-equity-financing

Dario priced a $22.4 million private placement of convertible preferred stock, priced at the market under Nasdaq rules, with pa...

 dariohealth-has-acquired-twill-to-create-comprehensive-digital-offerings-for-chronic-conditions-dario-paid-10m-in-cash-and-agreed-to-issue-approximately-10m-shares-in-the-form-of-pre-funded-warrants

Expecting nearly doubling Dario's pro forma revenues in 2023 Acquisition is immediately accretive to revenue and gross mar...

 darios-cardiometabolic-announces-contract-to-provide-cardiometabolic-solutions-to-regional-union-financial-terms-not-disclosed

Dario's integrated solution to support improved whole health gains traction in public and labor market

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION